Home Cart Sign in  
Chemical Structure| 192441-08-0 Chemical Structure| 192441-08-0

Structure of Lomeguatrib
CAS No.: 192441-08-0

Chemical Structure| 192441-08-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lomeguatrib, an inhibitor of DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) with IC50 of 0.009 μM in cell-free extracts from HeLa S3 cells, is a modified guanine base.

Synonyms: PaTrin-2

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lomeguatrib

CAS No. :192441-08-0
Formula : C10H8BrN5OS
M.W : 326.17
SMILES Code : NC1=NC(OCC2=CC(Br)=CS2)=C3N=CNC3=N1
Synonyms :
PaTrin-2
MDL No. :MFCD23703756
InChI Key :JUJPKFNFCWJBCX-UHFFFAOYSA-N
Pubchem ID :3025944

Safety of Lomeguatrib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Lomeguatrib

epigenetics

Isoform Comparison

Biological Activity

Target
  • Transferase

    O6-alkylguanine-DNA-alkyltransferas, IC50:5 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF-7 cells 6 nM 2 hours To investigate the effect of Lomeguatrib on MGMT activity in MCF-7 cells, results showed that Lomeguatrib effectively inactivated MGMT PMC2361498
MCF-7 cells 10 µM 2 hours To investigate the effect of Lomeguatrib on the growth inhibitory effects of temozolomide in MCF-7 cells, results showed that Lomeguatrib significantly enhanced the growth inhibitory effects of temozolomide PMC2361498
MGMT-UM GSCs 10 µM 72 hours To evaluate the inhibitory effect of Lomeguatrib on MGMT-UM GSCs, results showed that Lomeguatrib significantly reduced both MGMT protein and mRNA expression. PMC10606804
LN18 1 µM and 20 µM 24 hours Low concentrations of Lomeguatrib (1 µM) increased the radiosensitivity of LN18 cells, while high concentrations (20 µM) increased radioresistance. PMC8268804
T98G 1 µM and 20 µM 24 hours Low concentrations of Lomeguatrib (1 µM) increased the radiosensitivity of T98G cells, while high concentrations (20 µM) increased radioresistance. PMC8268804
U118 1 µM and 20 µM 24 hours Low concentrations of Lomeguatrib (1 µM) increased the radiosensitivity of U118 cells, while high concentrations (20 µM) increased radioresistance. PMC8268804

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Glioma xenograft model Intraperitoneal injection 150mg/kg Once daily for 1 week Enhanced sensitivity to TMZ PMC8025621
Nude mice MCF-7 human breast tumour xenograft model Intraperitoneal injection single injection at postnatal day 40 and observed until P300 To investigate the effect of Lomeguatrib in combination with temozolomide on the growth of MCF-7 xenografts, results showed that the combination significantly delayed tumour growth without a significant increase in toxicity PMC2361498
NCRNU athymic mice MGMT-UM GSCs intracranial xenograft model oral administration 8 mg/kg Once daily for three weeks To evaluate the effect of Lomeguatrib in combination with 5-Aza and TMZ on the survival of mice bearing MGMT-UM GSCs, results showed that the combination treatment significantly prolonged mice survival. PMC10606804

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.07mL

0.61mL

0.31mL

15.33mL

3.07mL

1.53mL

30.66mL

6.13mL

3.07mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories